Bladder cancer trials in Italy

In Italy 66 Also abroad 625

66 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Not yet taking people in Italy
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
Where
Milan, Reggio Emilia, Rome, Terni, Verona
Age
18 years and over
People
142 worldwide
Run by
Systimmune Inc.
See details and how to join2026-527617-29-00 · EU 2026-527617-29-00
Phase 1Taking people
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Where
Milan, Roma
Age
18 years and over
People
677 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05614739 · EU 2022-502755-59-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Milan, Reggio Emilia, Rome
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Where
Arezzo, Bergamo, Brescia, Milan, Romagnano, Rozzano, Torino
Age
18 years and over
People
641 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06319820
Phase 3Taking people
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Where
Bergamo, Brescia, Genoa, Milan, Naples, Orbassano, Rome, Udine
Age
18 years and over
People
220 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06919965 · EU 2024-519493-39-00
Phase 3Taking people
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Where
Arezzo, Genoa, Macerata, Milan, Naples, Orbassano, Rome, Rozzano, Verona
Age
18 years and over
People
590 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07419295 · EU 2024-520014-22-00
Phase 2Taking people
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Where
Bari, Foggia, Meldola, Milan
Age
18 years and over
People
240 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07475806
Phase 3Taking people
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Where
Rome, Rozzano
Age
18 years and over
People
454 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06510374 · EU 2024-512029-10-00
Phase 3Taking people
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Where
Castelfranco Veneto, Milan, Rome
Age
18 years and over
People
250 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06545955 · EU 2024-512177-27-01
Phase 2/3Taking people
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
Where
Bergamo, Brescia, Candiolo, Frattamaggiore, Genoa, Legnano, Milan, Naples, Orbassano, Pisa, Rome, Rozzano, Terni, Verona
Age
18 years and over
People
343 worldwide
Run by
Daiichi Sankyo Inc.
See details and how to join2024-516906-47-00 · EU 2024-516906-47-00
Phase 1/2Taking people
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Where
Verona
Age
18 years and over
People
45 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07222488 · EU 2025-520467-40-00
Phase 3Taking people
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Where
Lecce, Macerata, Meldola, Milan, Naples, Orbassano, Padova, Pisa, Rome, Rozzano, Verona
Age
18 years and over
People
390 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07566156 · EU 2026-525612-34-00
Phase 2Taking people
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Where
Frattamaggiore, Milan, Pisa, Rome
Age
18 years and over
People
90 worldwide
Run by
Tyra Biosciences, Inc
See details and how to joinNCT06995677 · EU 2025-521277-14-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bergamo, Genova, Naples, Verona
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Not yet taking people in Italy
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Milan, Naples
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 2Taking people
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Where
Florence, Orbassano, Rome
Age
18 years and over
People
150 worldwide
Run by
AstraZeneca
See details and how to joinNCT06960577 · EU 2024-519246-75-01
Phase 4Not yet taking people in Italy
ctDNA-guided Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma. The FUTURE Study
Where
Bergamo, Brescia, Catanzaro, Foggia, Genoa, Milan, Naples, Padova, Parma, Rome
Age
18 years and over
People
162
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to join2026-527171-28-00 · EU 2026-527171-28-00
Phase 3Taking people
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Where
Bari, Milan, Naples, Padova, Pisa, Roma, Rome
Age
18 years and over
People
450 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Ancona, Bologna, Florence, Milan, Naples, Ravenna
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Where
Arezzo, Milan, Rome
Age
18 years and over
People
308 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06833073 · EU 2024-517335-46-00
Phase 3Taking people
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
Where
Bari, Florence, Padova, Rome, Rozzano, Tricase
Age
18 years to 64 years
People
262 worldwide
Run by
AstraZeneca AB
See details and how to join2025-525030-57-00 · EU 2025-525030-57-00
Phase 1/2Taking people
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Where
Milan, Naples
Age
18 years and over
People
48 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05562830 · EU 2023-506384-34-00
Phase 2Taking people
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
Where
Arezzo, Aviano, Bari, Bologna, Florence, Foggia, Meldola, Milan, Modena, Naples, Orbassano, Padova, Parma, Rome, Rozzano
Age
18 years and over
People
88 worldwide
Run by
Astellas Pharma Global Development Inc.
See details and how to join2025-524488-18-00 · EU 2025-524488-18-00
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Meldola, Reggio Emilia, Roma
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444